1425927-75-8

Basic information

• Product Name: 2(1H)-Quinolinone, 6-amino-1,3-dimethyl-
• Synonyms: 2(1H)-Quinolinone, 6-amino-1,3-dimethyl-;6-amino-1,3-dimethyl-2(1H)-Quinolinone;6-Amino-1,3-dimethyl-1,2-dihydroquinolin-2-one;6-amino-1,3-dimethyl-1H-quinolin-2-one;6-amino-1,3-dimethylquinolin-2(1H)-one
• CAS NO: 1425927-75-8
• Molecular Formula: C₁₁H₁₂N₂O
• Molecular Weight: 188.22578
• EINECS: -0
• Mol File: 1425927-75-8.mol

Chemical Properties

• Boiling Point: 355.3±42.0 °C(Predicted)
• Appearance: /
• Density: 1.196±0.06 g/cm3(Predicted)
• PKA: 4.75±0.20(Predicted)
• CAS DataBase Reference: 2(1H)-Quinolinone, 6-amino-1,3-dimethyl-(CAS DataBase Reference)
• NIST Chemistry Reference: 2(1H)-Quinolinone, 6-amino-1,3-dimethyl-(1425927-75-8)
• EPA Substance Registry System: 2(1H)-Quinolinone, 6-amino-1,3-dimethyl-(1425927-75-8)

Safety Data

• Hazardous Substances Data: 1425927-75-8(Hazardous Substances Data)

Usage

Potential pharmacological properties

anti-cancer agent, anti-inflammatory agent, modulator of neurotransmitter activity

Potential antimicrobial properties

inhibits the growth of certain bacteria and fungi.

Upstream product

• 55539-83-8 1,3-dimethylquinolin-2-(1H)-one 
• 612-58-8 3-methylquinoline 
• 1873-55-8 3-methylquinoline N-oxide 
• 2721-59-7 3-methylcarbostyril 
• 1425927-74-7 1,3-dimethyl-6-nitroquinolin-2-(1H)-one 
• 1425927-69-0 3-methyl-6-nitro-1H-quinolin-2-one 

Downstream Products

• 1425927-10-1 N-(1,3-dimethyl-2-oxo-1,2-dihydroquinolin-6-yl)-2-methoxybenzenesulfonamide 
• 1884640-99-6 4-cyano-N-(1,3-dimethyl-2-oxo-1,2-dihydroquinolin-6-yl)benzenesulfonamide 

Relevant articles and documents

Design, synthesis, and biological evaluation of dual targeting inhibitors of histone deacetylase 6/8 and bromodomain BRPF1

Histone modifying proteins, specifically histone deacetylases (HDACs) and bromodomains, have emerged as novel promising targets for anticancer therapy. In the current work, based on available crystal structures and docking studies, we designed dual inhibitors of both HDAC6/8 and the bromodomain and PHD finger containing protein 1 (BRPF1). Biochemical and biophysical tests showed that compounds 23a,b and 37 are nanomolar inhibitors of both target proteins. Detailed structure-activity relationships were deduced for the synthesized inhibitors which were supported by extensive docking and molecular dynamics studies. Cellular testing in acute myeloid leukemia (AML) cells showed only a weak effect, most probably because of the poor permeability of the inhibitors. We also aimed to analyse the target engagement and the cellular activity of the novel inhibitors by determining the protein acetylation levels in cells by western blotting (tubulin vs histone acetylation), and by assessing their effects on various cancer cell lines.

Design of a biased potent small molecule inhibitor of the bromodomain and PHD finger-containing (brpf) proteins suitable for cellular and in vivo studies

The BRPF (bromodomain and PHD finger-containing) family are scaffolding proteins important for the recruitment of histone acetyltransferases of the MYST family to chromatin. Evaluation of the BRPF family as a potential drug target is at an early stage although there is an emerging understanding of a role in acute myeloid leukemia (AML). We report the optimization of fragment hit 5b to 13-d as a biased, potent inhibitor of the BRD of the BRPFs with excellent selectivity over nonclass IV BRD proteins. Evaluation of 13-d in a panel of cancer cell lines showed a selective inhibition of proliferation of a subset of AML lines. Pharmacokinetic studies established that 13-d had properties compatible with oral dosing in mouse models of disease (Fpo 49%). We propose that NI-42 (13-d) is a new chemical probe for the BRPFs suitable for cellular and in vivo studies to explore the fundamental biology of these proteins.

QUINOLONES AS INHIBITORS OF CLASS IV BROMODOMAIN PROTEINS

The present invention provides compounds of formula (I) as described herein and pharmaceutically acceptable salts, hydrates and solvates thereof for use in medicine, for example in the treatment of acute myeloid leukaemia:

NOVEL HETEROCYCLIC COMPOUNDS AS BROMODOMAIN INHIBITORS

Disclosed are compounds of Formula (I): (I) which are useful as bromodomain inhibitors. Pharmaceutical compositions containing compounds of Formula (I) and the use of compounds of Formula (I) to treat diseases or disorders that are bromodomain-dependent are also disclosed. Methods for preparing and using these compounds are further described.